文献速递骨质疏松与代谢性骨病

评估COVID-19对英格兰2019至2023年DXA等待名单和骨质疏松处方趋势的影响

Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019-2023.
PubMed 文献 · Osteoporos Int · 2024-05-25

本研究利用英国国家医疗服务体系(NHS)等待时间和骨质疏松药物社区处方数据集,评估COVID-19对英格兰DXA等待和骨质疏松药物模式的影响。结果显示DXA等待名单时间显著增加且处方率存在差异,需要投资以改善等待名单时间。

要点

  • 英格兰DXA年平均等待名单长度从2019年的31,851增至2023年的65,757。
  • 等待DXA超过6周的患者比例从2019年的0.9%升至2020年的40%。
  • 等待超过13周的患者比例从2019年的0.1%升至2020年的16.7%。

核心结论

  • COVID-19显著增加了DXA扫描等待名单且恢复面临持续挑战。
  • 英格兰各地DXA服务可及性存在明显差异。
  • 以药物处方衡量的骨质疏松照护在大流行期间也有所下降。
  • 解决这些问题需要有重点的投资和努力以改善DXA扫描等待时间和英格兰骨质疏松照护的整体可及性。

研究设计与样本

  • 分析2019年3月至2023年6月的数据,包括NHS数字诊断等待时间(DM01)和来自英格兰处方数据集(EPD)的骨质疏松药物处方。
  • 涵盖英格兰七个地区的总等待名单数据以及各种骨质疏松药物的处方模式。
  • 分析包括总活动量数据和回归分析以估计无COVID-19时的预期活动量,所有数据分析使用R。

主要发现

  • 英格兰DXA等待名单显著增长,年平均等待名单长度从2019年的31,851增至2023年的65,757。
  • 等待DXA超过6周的患者比例从2019年的0.9%升至2020年的40%。
  • 等待超过13周的患者比例从2019年的0.1%升至2020年的16.7%。
  • 处方趋势各异,地舒单抗、伊班膦酸和利塞膦酸钠增加,而阿仑膦酸、雷洛昔芬盐酸盐和特立帕肽减少。
  • 2020年第二季度出现显著的总体处方下降。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: This study uses NHS waiting times and osteoporosis medication community prescription datasets to assess the impact of COVID-19 on DXA waits and osteoporosis medication patterns in England. Results show significant increases in DXA waiting list times and variation in prescription rates. Investment is needed to improve waiting list times. PURPOSE: This study investigates the impact of COVID-19 on DXA scan waiting lists, service recovery and osteoporosis medication prescriptions in the NHS following the March 2020 national lockdowns and staff redeployment. METHODS: Data from March 2019 to June 2023, including NHS digital diagnostics waiting times (DM01) and osteoporosis medication prescriptions from the English Prescribing Dataset (EPD), were analysed. This encompassed total waiting list data across England's seven regions and prescribing patterns for various osteoporosis medications. Analyses included total activity figures and regression analysis to estimate expected activity without COVID-19, using R for all data analysis. RESULTS: In England, DXA waiting lists have grown significantly, with the yearly mean waiting list length increasing from 31,851 in 2019 to 65,757 in 2023. The percentage of patients waiting over 6 weeks for DXA scans rose from 0.9% in 2019 to 40% in 2020, and those waiting over 13 weeks increased from 0.1% in 2019 to 16.7% in 2020. Prescription trends varied, with increases in denosumab, ibandronic acid and risedronate sodium and decreases in alendronic acid, raloxifene hydrochloride and teriparatide. A notable overall prescription decrease occurred in the second quarter of 2020. CONCLUSION: COVID-19 has significantly increased DXA scan waiting lists with ongoing recovery challenges. There is a noticeable disparity in DXA service access across England. Osteoporosis care, indicated by medication prescriptions, also declined during the pandemic. Addressing these issues requires focused investment and effort to improve DXA scan waiting times and overall access to osteoporosis care in England.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Knight KJ, Fordham RJ, Crabtree NJ, et al. Evaluating the impact of COVID-19 on DXA waiting lists and osteoporosis prescription trends in England 2019-2023. Osteoporos Int. 2024. PMID: 38795142. doi:10.1007/s00198-024-07120-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。